Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
doxorubicin + vincristine + etoposide + mitotane
- Development stage
- Unknown
- Lead developer
- National Cancer Institute
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This is a combination chemotherapy regimen used in the treatment of advanced adrenocortical carcinoma (ACC). The regimen consists of doxorubicin (an anthracycline antibiotic), vincristine (a vinca alkaloid), etoposide (a topoisomerase inhibitor), and mitotane (an adrenocortical cytotoxic agent). Mitotane is often administered orally at doses up to 4 g/day with the goal of attaining blood levels of 14-20 mg/L, while the other components are administered intravenously. This combination has been studied in clinical trials for patients with metastatic adrenocortical carcinoma not amenable to radical surgery.
02
Targets
Adrenal cortical mitochondrial proteinsTOP2A (DNA topoisomerase II)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on doxorubicin + vincristine + etoposide + mitotane.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on doxorubicin + vincristine + etoposide + mitotane.